S
Suzhou Panomic Biomedical Technology
A biotech company providing a wide range of state-of-the-art, research-grade assays trusted by clinicians and scientists
About Suzhou Panomic Biomedical Technology
Suzhou Panomic Biomedical Technology, also known as PANOMIX, was established in 2013 within the Suzhou Industrial Park. The company's core team hails from prestigious institutions such as Harvard University, MD Anderson Cancer Center, and the Chinese Academy of Sciences. As a contract research organization (CRO), PANOMIX specializes in metabolomics technology, offering comprehensive solutions for precision medicine and nutrition. The firm operates across several business segments, including scientific research services, industrial services, new drug support, and clinical detection. Its client base consists of universities, research institutes, hospitals, and various enterprises, serving over 1,000 customers.
The company's business model is centered on providing data analysis services and a wide array of research-grade assays. PANOMIX is equipped with over 80 advanced mass spectrometry systems, enabling it to deliver more than 100 distinct detection and analysis services and over 20 clinical detection products. Its service portfolio is extensive, featuring global untargeted metabolomics, targeted metabolomics, lipidomics, proteomics, and multi-omics integrated analysis. A key offering is its independently developed "Global untargeted metabolomics" technology platform and the BioDeepTM cloud data analysis system, which together form an integrated platform for metabolomics research. The company also develops products for diagnosing and screening cardiovascular diseases, strokes, and tumors.
Financially, the company is classified as a Series A startup. It has secured significant investment to fuel its growth, completing a funding round on April 29, 2021, that raised $15.4 million. This positions PANOMIX to continue its focus on the research and clinical application development of metabolomics technology.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2023 | $14M | $75M | Oriza Holdings · Leading Venture Capital · Yuansheng BioVenture | ↗ |
| SERIES A✓Equity / VC | May 2021 | $15M | $60M | YuanBio Venture Capital | — |
Growth signals
Latest recorded traffic for Suzhou Panomic Biomedical Technology is 330 monthly website visits. Suzhou Panomic Biomedical Technology's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Panomic Biomedical Technology in the Suzhou Shi ecosystem
The Suzhou Panomic Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- YCYuanBio Venture Capital
Oriza Holdings- LCLeading Venture Capital
Yuansheng BioVenture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Panomic Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Panomic Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








